Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0918443.3Aexternal-prioritypatent/GB0918443D0/en
Priority claimed from GBGB1017363.1Aexternal-prioritypatent/GB201017363D0/en
Application filed by Owen Munford LtdfiledCriticalOwen Munford Ltd
Priority claimed from PCT/GB2010/051774external-prioritypatent/WO2011048422A2/en
Publication of BR112012009491A2publicationCriticalpatent/BR112012009491A2/en
Infusion, Injection, And Reservoir Apparatuses
(AREA)
Abstract
autoinjetor. é descrito um autoinjetor que compreende um alojamento (10) para receber uma seringa (14), e um mecanismo de acionamento compreendendo primeira e segunda molas (30,32) que operam em tandem por meio de um elemento intermediário (34), em um êmbolo (42). o êmbolo é retido em uma posição travada por um gatilho. a liberação do gatilho faz com que a primeira mola avance a seringa até um ponto de retenção, após o qual a segunda mola na seringa expele uma dose.autoinjector. An autoinjector comprising a housing (10) for receiving a syringe (14), and a drive mechanism comprising first and second springs (30,32) operating in tandem by means of an intermediate element (34) on a plunger (42). The plunger is held in a locked position by a trigger. releasing the trigger causes the first spring to advance the syringe to a retention point, after which the second spring in the syringe expels a dose.
Medication delivery device comprising; a dosing mechanism comprising; a piston rod; an actuator device; a dose setting member; a dose limiting member; and a varcasa that houses at least part of the dosing mechanism.
Medication delivery device comprising; a casing; a medication receptacle; a dosing mechanism with a piston rod and an actuator device, wherein the medication receptacle has an actuation means for bringing a guide means from a guide position to a piston rod guide position.
Use of a pharmaceutical composition comprising an inhibitor of sglt2 (1-chloro-4- (bd-glucopyranos-1-yl) -2- [4 - ((s) -tetrahydrofuran-3-yloxy) -benzyl] -benzene, to improve glycemic control.
Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
Free format text:
EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2536 DE 13-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.
B350
Update of information on the portal [chapter 15.35 patent gazette]